Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Aug 9;25(1):571.
doi: 10.1186/s12876-025-04138-w.

Early assessment of treatment response in primary biliary cholangitis: key to timely management

Tomas Koky  1 , Sylvia Drazilova  2   3 , Martin Janicko  1 , Dominika Toporcerova  1 , Jakub Gazda  1 , Peter Jarcuska  1
Affiliations
Multicenter Study

Early assessment of treatment response in primary biliary cholangitis: key to timely management

Tomas Koky et al. BMC Gastroenterol. .

Abstract

Aim: The aim of our study was to explore predictive factors associated with compete biochemical response (CBR) in primary biliary cholangitis (PBC) patients treated with ursodeoxycholic acid (UDCA) at month 12 and at last check-up; CBR was defined as both normal bilirubin and ALP levels. We also evaluated hepatic decompensation and prognosis during UDCA treatment.

Methods: We conducted a multicenter retrospective study of PBC patients. We enrolled patients with PBC before the beginning of UDCA treatment (13-15 mg/kg body weight per day) between 1999 and 2024 in 2 hepatology centers in Eastern Slovakia.

Results: We enrolled 155 patients in the final analysis, 147 women and 8 men, mean age at diagnosis 57 ± 15 years, the median follow-up was 10 ± 8 years. 29 patients (18.7%) had cirrhosis at diagnosis. Hepatic decompensation occurred in 12 patients during follow-up (7.7%; 95%CI 4-13%). 114 patients (73.5%; 95% CI 66-80%) achieved response to treatment according to Toronto criteria at month 6; CBR after 12 months of treatment was achieved by 41.3% (95% CI 33-50%) of patients; 51 patients (32.9%; 95% CI 26-41%) achieved CBR at last check-up. The OR for achieving CBR at month 12 in Toronto responders at month 6 was 46.36 (95%CI 6.147-349.646); p < 0.001. Of the patients who achieved a response defined by Toronto criteria at month 6, 44.7% of patients achieved CBR at last check-up and 55.3% did not. Out of the patients who did not achieve Toronto at month 6, none achieved CBR at last check-up (0%). Treatment response by Toronto criteria at month 6, CBR at month 12 and absence of liver cirrhosis predicted CBR at last check-up. The odds of decompensation were about 90% lower in patients who achieved treatment response. No case of hepatic decompensation or liver-related mortality during follow-up was observed in patients with CBR at last check-up.

Conclusion: The assessment of treatment response at month 6 is very accurate predictor of complete biochemical response throughout the course of the disease. For non-responders to UDCA treatment, the addition of second line PBC treatment is indicated. For patients who have not met Toronto criteria at month 6 of UDCA treatment, the addition of second line PBC therapy should be considered.

Keywords: Liver decompensation; Primary biliary cholangitis; Prognosis; Second line treatment; Treatment response; Ursodeoxycholic acid.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics and consent to participate: The study protocol is in accordance with the 1964 Helsinki declaration, its later amendments, and the principles of good clinical practice. The study protocol was approved by the Ethical committee of Poprad Hospital, a.s. on 5 May 2019 and by Ethical committee of L Pasteur University Hospital on 22 October 2020. The committee waived the need for the specific patients. informed consent due to the retrospective nature of the data collection. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Probability of liver cirrhosis decompensation during follow-up in groups with treatment response defined by Toronto criteria at month 6 (panel A), p=0.011; treatment response defined by complete biochemical response at month 12 (panel B), p=0.038; treatment response defined by complete biochemical response at last check-up (panel C), p=0.026
Fig. 2
Fig. 2
Recommendation of treatment algorithm for primary biliary cholangitis patients
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. European Association for the Study of the Liver. Electronic address eee, European association for the study of the L: EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. - PubMed
    1. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American association for the study of liver diseases. Hepatology. 2022;75(4):1012–3. - PubMed
    1. Gazda J, Drazilova S, Janicko M, Jarcuska P. The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol. 2021;2021:9151525. - PMC - PubMed
    1. Muratori L, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G, Carini R, Lenzi M, Landini MP, Albano E, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut. 2000;46(4):553–61. - PMC - PubMed
    1. Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, Ferri S, C DEM, Lenzi M, et al. Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim-like/membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24(11–12):1575–83. - PubMed

Publication types

LinkOut - more resources